An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Cellebrite DI Ltd.
VERDICT
The label
Markup
read at $15.44
Cellebrite DI Ltd. holds its Markup at $15.44.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 6 days
Price
$15.44
Valuation
55.14 trailing · 23.36 forward price to earnings
Values screen
PASS· score 94.7
Beta
1.17
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads FAIR VALUE — it trades at roughly a 20% discount to our $18.59 fair value, moderate competitive moat, 19.30% revenue growth.
Read at
$15.44
55.14 P/E · 23.36 fwd
Our fair value
$18.59
20% discount
Analyst target (avg)
$20.00
+30% to current
Target low $15.00Analyst target rangeTarget high $28.00
▲ current $15.44 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$15.44
you are here
Conservative
$13.50
-13%
Analyst avg
$20.00
+30%
Our fair value
$18.59
+20%
Analyst high
$28.00
+81%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
19.30%
Profit margin
14.48%
Debt to equity
4.47
Analyst consensus
Strong Buy · 7 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 0.7% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 13.4% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Cellebrite Turns Seized Phones Into Courtroom Evidence
Every time police in London or Tel Aviv pull a locked phone from a suspect, someone has to turn that data into usable evidence without breaking the law. Cellebrite builds the tools that do exactly that, moving bits from devices into review platforms that investigators actually trust. The business sits in a narrow lane where demand keeps rising as crimes move online.
Revenue is growing 19 percent, margins sit at 14 percent and return on equity reaches 16 percent, all while the shares trade at 23.4 times forward earnings against a fair-value estimate 20 percent higher. A moderate moat and a clean ethical screen support the case for steady compounding rather than explosive growth. Analyst targets cluster around 20 dollars, which lines up with the current pricing leaving limited room for error.
Israel-based operations bring currency and geopolitical risk that can swing results quickly, and competition from bigger software names could cap pricing power over time. The moderate moat means any slowdown in law-enforcement budgets would hit harder than the numbers currently suggest.
The risks · The things to watch: its business and earnings are exposed to Israel and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in CLBT's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
CLBT trades on Nasdaq (the company is based in Israel). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21. Entered 2026-07-24 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-24Markup$15.44+11.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-18Markup$13.81+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-03Markup$13.81+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$13.81Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
